Drugs / C-4-29
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04861480 | Jun 2021 → Dec 2023 | plasma cell myeloma | Chongqing Precision Biotech Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C-4-29 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04861480 ↗ |
| Route | Intravenous | “C-4-29 cells will be infused to the subject by intravenous infusion.” NCT04861480 ↗ |